Abstract
Prostate cancer may be suspected by digital rectal examination (DRE), serum marker abnormality, or transrectal ultrasound of the prostate (TRUS), but its presence must be confirmed by biopsy. A TRUS-guided biopsy results in greater accuracy of tissue sampling than does biopsy under digital guidance. A TRUS biopsy is indicated in patients in whom tactile biopsy has yielded negative results, as well as in patients with sonographically visible areas of suspicion. Six-sextant biopsy under TRUS guidnce is helpful in diagnosing cancers that are neither tactilely nor sonographically evident but whose presence is suspected by inordinate elevation of serum prostate-specific antigen (PSA).
Get full access to this article
View all access options for this article.